BioCentury
ARTICLE | Clinical News

Polaris' ADI-PEG 20 meets in Phase II mesothelioma trial

October 29, 2013 12:46 AM UTC

Polaris Pharmaceuticals Inc. (San Diego, Calif.) said once-weekly intramuscular ADI-PEG 20 plus best supportive care (BSC) for six months met the primary endpoint of improving median progression-free ...